English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 904096      Online Users : 846
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version
    Siblings
    期刊論文 [100/101]

    Collection Statistics

    近3年內發表的文件:2(8.33%)
    含全文筆數:19(79.17%)

    文件下載次數統計
    下載大於0次:19(100.00%)
    下載大於100次:19(100.00%)
    檔案下載總次數:10506(16.31%)

    最後更新時間: 2024-12-01 00:01


    Top Upload

    Loading...

    Top Download

    Loading...

    RSS Feed RSS Feed
    Jump to a point in the index:
    Or type in a year:
    Ordering With Most Recent First Show Oldest First

    Showing items 1-24 of 24. (1 Page(s) Totally)
    1 
    View [10|25|50] records per page

    DateTitleRelation
    2022-07 Potential roles of gut microbiome in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors Annals of Oncology. 2022 Jul;33(Suppl. 6):S484.
    2022-02-01 A prospective phase II study of biweekly S-1, leucovorin and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma Journal of Clinical Oncology. 2022 Feb 01;40(4, Suppl.):550.
    2021-07 Atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma and chronic hepatitis B virus infection with high viral load Annals of Oncology. 2021 Jul;32(Suppl. 3):S141-S142.
    2021-05 A phase 2 study of liposomal irinotecan with 5-fluorouracil and leucovorin in squamous cell carcinoma of head and neck or esophagus after prior platinum-based chemotherapy or chemoradiotherapy Journal of Clinical Oncology. 2021 May;39(15, Suppl.):Abstract number 6025.
    2020-02 Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in pat Cancer Research. 2020 Feb;80(4, Suppl.):Meeting Abstract GS1-04.
    2019-05 An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14) Journal of Clinical Oncology. 2019 May;37(15, Suppl. S):Abstract number 4101.
    2018-01 The association between lifestyle factors and oral potentially malignant disorders in Taiwan Cancer Science. 2018 Jan;109(Suppl. 1):325.
    2017-07-31 The treatment patterns of non-metastatic prostate cancer in an Asian country International Journal of Urology. 2017 Jul 31;24(Suppl. S1):98.
    2017-05 Prevalence and estimated trend in chemotherapy use near death from population-based studies on cancer patients: A systematic review and meta-analysis Journal of Clinical Oncology. 2017 May;35(Suppl. 15):Meeting Abstract 6590.
    2017 Prediction of hepatitis B virus reactivation in lymphoma patients with resolved hepatitis B virus infection who received rituximab-containing chemotherapy: The roles of antiHBc/antiHBs quantification Journal of Hepatology. 2017;66(1, Suppl.):S259.
    2016-10-01 The prognostic impact of overall treatment time on disease outcomes of uterine cervical cancer patients: A nationwide cohort study of Taiwan International Journal of Radiation Oncology, Biology, Physics. 2016 Oct 1;96(2S, Suppl.):E301.
    2016-10-01 The influence of hospital volume on disease outcomes of advanced uterine cervical cancer patients: A nationwide cohort study of Taiwan International Journal of Radiation Oncology, Biology, Physics. 2016 Oct 1;96(2S, Suppl.):S15-S16.
    2016-10 The role of pre-treatment plasma Epstein-Barr virus (EBV) DNA as a predictive biomarker of induction chemotherapy for stage IVA or IVB nasopharyngeal carcinoma (NPC) patients - A Subgroup Analysis on Taiwan Cooperative Oncology Group (TCOG) 1303 study Annals of Oncology. 2016 Oct;27(Suppl.6 ):Meeting Abstract 973P.
    2015-12 A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma-TCOG 3211 clinical trial Journal of Gastroenterology and Hepatology. 2015 Dec;30(Suppl. S4):99.
    2015-05 A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma: The TCOG T3211 trial Journal of Clinical Oncology. 2015 May;33(15, Suppl.):4024.
    2015-04 Long-term outcome of chemotherapy-induced HBV reactivation in lymphoma patients with resolved HBV infection Journal of Hepatology. 2015 Apr;62, Suppl. 2:S563.
    2011-09 Use of chemotherapy at the end of life among Taiwanese cancer decedents, 2001-2006 European Journal of Cancer. 2011 Sep;47(Suppl 1):S229-S230.
    2009-09 Performance of medical oncologists on end-of-life care for Taiwanese cancer decedents, 2001-2006 EJC Supplements. 2009 Sep;7(2):179.
    2009-09 Synergistic augmentation of arsenic trioxide-induced cytotoxicity by BCNU through reactive oxygen species-related autophagic pathway in human solid tumors EJC Supplements. 2009 Sep;7(3):16.
    2007 A prospective comparative study of prophylactic or therapeutic use of lamivudine for chemotherapy-associated hepatitis B (HBV) reactivation in nowhodgkin's lymphoma (NHL) patients Journal of Hepatology. 2007;46(Suppl. 1):S297.
    2006-01 Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinoma Head and Neck. 2006 Jan;28(1):74-80.
    2005-05-20 Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma Journal of Clinical Oncology. 2005 May;23(15):3568-3576.
    2002 Phase I and pharmacokinetic studies of oral thalidomide in advanced hepatocellular carcinoma International Journal of Cancer. 2002;Suppl. 13:336-337.
    1999-09 A multi-centre phase II trial of gemcitabine (GEM) and vinorelbine (VRL) in patients (PTS) with stage III-IV non small cell lung cancer (NSCLC) European Journal of Cancer. 1999 Sep;35:S259.

    Showing items 1-24 of 24. (1 Page(s) Totally)
    1 
    View [10|25|50] records per page

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback